

Edgar Filing: BIOGENTECH CORP - Form 10QSB

BIOGENTECH CORP
Form 10QSB
August 27, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2003

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 For the transition period from _____ to _____

Commission File Number: 000-49620

Biogentech Corp.

(Exact name of small business issuer as specified in its charter)

Nevada

91-1868007

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer Identification No.)

2445 McCabe Way, Suite 150, Irvine, California 92614

(Address of principal executive offices)

(949) 757-0001

(Issuer's Telephone Number)

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

No

X

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practical date. As of August 25, 2003 there were 8,532,000* shares of the issuer's \$.001 par value common stock issued and outstanding.

*Represents stock issued and outstanding in Biogentech Corp., the reporting issuer. The attached financial statements reflect a total of 20,864,708 shares issued and outstanding as of June 30, 2003. That will be the number of shares issued and outstanding when the Biogentech Corp. stock is issued to the

Edgar Filing: BIOGENTECH CORP - Form 10QSB

Biogenetec Incorporated shareholders in exchange for their Biogenetec Incorporated stock. Also 4,500,000 shares of Biogentch Corp's common stock will be cancelled as part of the reverse acquisition. An internal review of Biogenetec Incorporated's shareholder register and related supporting documents was undertaken concurrently with the merger, prior to passing such records to the transfer agent for the issuance of the exchanged shares. The review project is complete and the stock register will be forwarded to the transfer agent for processing.

1

PART 1 FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS -- The financial statements included in this filing are the historical financial statements of BioGentec Incorporated, the accounting acquirer in the reverse merger with the acquisition subsidiary of BioGentech Corp. (formerly Togs for Tykes, Inc.). The reverse merger was not consummated until July 2, 2003 but as Biogenetec Incorporated was deemed the accounting acquirer, and as allowed under statement of financial accounting standards number 141("SFAS 141"), the company designated for accounting purposes a date of convenience for the closing of June 30, 2003. (See footnote 1 for further explanation.)

BioGentech Corp. and Subsidiary
(a Development Stage Company)
CONSOLIDATED BALANCE SHEETS

| | June 30, 2003 (Unaudited) |
|---|------------------------------|
| ASSETS | |
| CURRENT ASSETS | |
| CASH | \$ 10,858 |
| RESTRICTED CASH | - |
| INVENTORY | 5,903 |
| OTHER ASSETS | 545 |
| | ----- |
| TOTAL CURRENT ASSETS | 17,306 |
| PROPERTY AND EQUIPMENT, NET | 79,382 |
| WEBSITE DEVELOPMENT COST, NET | 12,650 |
| PATENTS, NET | 3,850,000 |
| DEPOSIT | 40,000 |
| | ----- |
| TOTAL ASSETS | \$ 3,999,338 |
| | ===== |
| LIABILITIES AND STOCKHOLDERS' EQUITY | |
| CURRENT LIABILITIES | |
| ACCOUNTS PAYABLE AND ACCRUED EXPENSES | \$ 452,466 |
| DUE TO RELATED PARTIES | 597,133 |
| | ----- |
| TOTAL CURRENT LIABILITIES | 1,049,599 |
| | ----- |
| COMMON STOCK - \$.001 par value | |

Edgar Filing: BIOGENTECH CORP - Form 10QSB

| | |
|---|--------------|
| 50,000,000 shares authorized, 20,864,708 and 19,732,708 issued and outstanding , respectively | 20,865 |
| ADDITIONAL PAID IN CAPITAL | 7,004,913 |
| DEFERRED COMPENSATION | (112,000) |
| DEFICIT ACCUMULATED DURING THE DEVELOPMENT STAGE | (3,964,039) |
| | ----- |
| TOTAL STOCKHOLDERS' EQUITY | 2,949,739 |
| | ----- |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | \$ 3,999,338 |
| | ===== |

The accompanying notes are an integral part of the
consolidated financial statements

2

BIOGENTECH CORP. AND SUBSIDIARY CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (a Development Stage Company)

| | Three months ended June 30, | | |
|--|-----------------------------|--------------|-----------------------------------|
| | 2003 | 2002 | Cumul inc thro 30 --- |
| NET SALES | \$ 1,687 | \$ 117 | \$ |
| COST OF SALES | 439 | 6,447 | |
| | ----- | ----- | ----- |
| GROSS PROFIT (LOSS) | 1,248 | (6,330) | |
| | ----- | ----- | ----- |
| OPERATING EXPENSES | | | |
| DEPRECIATION & AMORTIZATION | 5,249 | 5,117 | |
| GENERAL AND ADMINISTRATIVE EXPENSES | 642,176 | 742,167 | 3 |
| | ----- | ----- | ----- |
| TOTAL OPERATING EXPENSES | 647,425 | 747,284 | 3 |
| | ----- | ----- | ----- |
| LOSS FROM OPERATIONS | (646,177) | (753,614) | (3 |
| OTHER INCOME (EXPENSE) | | | |
| INTEREST EXPENSE | (6,949) | (31,030) | |
| | ----- | ----- | ----- |
| LOSS BEFORE PROVISION FOR INCOME TAXES | (653,126) | (784,644) | (3 |
| | ----- | ----- | ----- |
| PROVISION FOR INCOME TAXES | - | - | |
| | ----- | ----- | ----- |
| NET LOSS | \$ (653,126) | \$ (784,644) | \$ (3 |

Edgar Filing: BIOGENTECH CORP - Form 10QSB

| | | | |
|---|------------|------------|----|
| LOSS PER COMMON SHARE - BASIC AND DILUTED | \$ (0.03) | \$ (0.05) | |
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING | 19,817,875 | 16,978,933 | 17 |

The accompanying notes are an integral part of the consolidated financial statements

3

BIOGENTECH CORP. AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)

| | Common stock | | Additional paid-in capital | Deferred compensation | ac d de |
|--|--------------|--------|----------------------------------|--------------------------|---------------|
| | Shares | Amount | | | |
| Balance at inception (November 21, 2000) | - | \$ - | \$ - | - | |
| Issuance of founder's shares in exchange for property and equipment | 16,300,000 | 16,300 | - | - | |
| Issuance of common stock for cash - November 2000 @ \$1.00 | 30,000 | 30 | 29,970 | - | |
| Issuance of common stock for cash - December 2000 @ \$1.00 | 15,000 | 15 | 14,985 | - | |
| Issuance of common stock for cash - February 2001 @ \$1.00 | 12,000 | 12 | 11,988 | - | |
| Issuance of common stock for cash - March 2001 @ \$1.00 | 125,000 | 125 | 124,875 | - | |
| Issuance of common stock for services - March 2001 @ \$1.00 | 10,000 | 10 | 9,990 | - | |
| Contributed capital (see Notes 5 and 10) | - | - | 62,681 | - | |
| Net loss for the period from inception (November 21, 2000) | | | | | |

Edgar Filing: BIOGENTECH CORP - Form 10QSB

| | | | | |
|---|------------|--------|---------|---|
| to March 31, 2001 | - | - | - | - |
| Balance at March 31, 2001 | 16,492,000 | 16,492 | 254,489 | - |
| Issuance of common stock for cash - April 2001 @ \$1.00 | 10,000 | 10 | 9,990 | - |

4

BIOGENTECH CORP. AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)

| | | | | |
|--|--------|----|--------|---|
| Issuance of common stock for telephone equipment - April 2001 @ \$1.00 | 6,750 | 7 | 6,743 | - |
| Issuance of common stock for cash - May 2001 @ \$1.00 | 11,000 | 11 | 10,989 | - |
| Issuance of common stock for website development - May 2001 @ \$1.00 | 17,000 | 17 | 16,983 | - |
| Issuance of common stock for legal services - May 2001 @ \$1.00 | 1,000 | 1 | 999 | - |
| Issuance of common stock for cash - June 2001 @ \$1.00 | 23,500 | 24 | 23,476 | - |
| Issuance of common stock for cash - July 2001 @ \$1.00 | 20,000 | 20 | 19,980 | - |
| Issuance of common stock for cash - August 2001 @ \$1.00 | 25,000 | 25 | 24,975 | - |

The accompanying notes are an integral part of the consolidated financial statements

5

Edgar Filing: BIOGENTECH CORP - Form 10QSB

BIOGENTECH CORP. AND SUBIDIARY
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (CONTINUED)

| | Common stock | | Additional paid-in capital | Deferred compensatio |
|--|--------------|--------|----------------------------------|-------------------------|
| | Shares | Amount | | |
| Issuance of common stock for services, related party - | | | | |
| September 2001 @ \$1.00 | 65,858 | 66 | 65,792 | |
| Issuance of common stock for cash - | | | | |
| September 2001 @ \$1.00 | 15,000 | 15 | 14,985 | |
| Issuance of common stock for services - | | | | |
| September 2001 @ \$1.00 | 11,000 | 11 | 10,989 | |
| Issuance of stock options for services - | | | | |
| September 2001 | - | - | 32,000 | |
| Issuance of common stock for cash - | | | | |
| October 2001 @ \$1.00 | 5,000 | 5 | 4,995 | |
| Issuance of common stock for cash - | | | | |
| December 2001 @ \$1.00 | 30,000 | 30 | 29,970 | |
| Issuance of common stock for services - | | | | |
| December 31, 2001 @ \$1.00 | 33,000 | 33 | 32,967 | |
| Issuance of common stock for services, related party - | | | | |
| December 2001 @ \$1.00 | 117,500 | 118 | 117,382 | |
| Issuance of common stock for prepaid advertising - | | | | |
| December 2001 @ \$1.00 | 15,600 | 15 | 15,585 | |
| Issuance of common stock for property and equipment - | | | | |
| January 2002 @ \$3.00 | 1,000 | 1 | 2,999 | |
| Issuance of common stock for services, related party - | | | | |
| January 2002 @ \$1.00 | 33,000 | 33 | 32,967 | |
| Issuance of common stock for cash - | | | | |
| February 2002 @ \$2.00 | 20,000 | 20 | 39,980 | |
| Issuance of common stock for cash - | | | | |
| March 2002 @ \$2.00 | 12,500 | 12 | 24,988 | |
| Contributed capital (see Notes 5 and 10) | - | - | 211,269 | |
| Deferred compensation | - | - | - | (60,100) |
| Net loss | - | - | - | - |
| | ----- | ----- | ----- | ----- |
| Balance at March 31, 2002 | 16,965,708 | 16,966 | 1,005,492 | (60,100) |

Edgar Filing: BIOGENTECH CORP - Form 10QSB

| | | | |
|---------------------------------------|--------|----|--------|
| Issuance of common stock for services | | | |
| - April 2002 @ \$2.00 | 3,000 | 3 | 5,997 |
| Issuance of common stock for cash - | | | |
| April 2002 @ \$1.00 | 10,000 | 10 | 9,990 |
| Issuance of common stock for cash - | | | |
| April 2002 @ \$2.00 | 17,500 | 17 | 34,983 |
| Issuance of common stock for cash - | | | |
| May 2002 @ \$1.00 | 10,000 | 10 | 9,990 |
| Issuance of common stock for cash - | | | |
| May 2002 @ \$2.00 | 16,000 | 16 | 31,984 |

The accompanying notes are an integral part of the consolidated financial statements

6

BIOGENTECH CORP. AND SUBIDIARY
STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (CONTINUED)

| | Common stock | | Additional paid-in capital | Deferred compensati |
|--|--------------|--------|----------------------------------|------------------------|
| | Shares | Amount | | |
| Issuance of stock options for services | | | | |
| - May 2002 | - | - | 350,000 | |
| Contributed capital - bonus expense (see Note 10) | - | - | 50,000 | |
| Issuance of common stock for cash - | | | | |
| June 2002 @ \$1.00 | 5,000 | 5 | 4,995 | |
| Issuance of common stock for cash - | | | | |
| June 2002 @ \$2.00 | 5,000 | 5 | 9,995 | |
| Issuance of common stock for cash - | | | | |
| July 2002 @ \$1.00 | 5,000 | 5 | 4,995 | |
| Issuance of common stock for cash - | | | | |
| August 2002 @ \$2.00 | 10,000 | 10 | 19,990 | |
| Issuance of common stock for cash - | | | | |
| September 2002 @ \$2.00 | 10,000 | 10 | 19,990 | |
| Issuance of stock options below fair market value - | | | | |
| November 2002 | - | - | 250,000 | (250,000) |
| Issuance of common stock for conversion of note - | | | | |
| December 2002 @ \$2.00 | 50,000 | 50 | 99,950 | |
| Issuance of common stock for cash - | | | | |
| December 2002 @ \$2.00 | 20,000 | 20 | 39,980 | |
| Issuance of common stock for services - | | | | |
| December 2002 | | | | |
| @ \$2.00 | 15,000 | 15 | 29,985 | |

Edgar Filing: BIOGENTECH CORP - Form 10QSB

| | | | | |
|--|------------|--------|-----------|-------|
| Issuance of common stock for patents - December 2002 @ \$2.00 | 2,000,000 | 2,000 | 3,998,000 | |
| Contributed capital (see Notes 5 and 10) | - | - | 292,718 | |
| Issuance of common stock for exercise of options - December 2002 | 574,000 | 574 | 574,028 | |
| Deferred compensation | - | - | - | 60, |
| Contributed capital (see Notes 5 and 10) | - | - | 5,000 | |
| Issuance of stock options for services - January 2003 | - | - | 25,000 | |
| Issuance of common stock for cash - February 2003 @\$2.00 | 11,500 | 12 | 22,988 | |
| Issuance of common stock for cash - March 2003 @\$2.00 | 5,000 | 5 | 9,995 | |
| Deferred compensation | - | - | - | 54, |
| Net loss | - | - | - | |
| Balance at March 31, 2003 | 19,732,708 | 19,733 | 6,906,045 | (196, |

The accompanying notes are an integral part of the consolidated financial statements

7

BIOGENTECH CORP. AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (CONTINUED)

| | Common stock | Shares | Additional paid-in capital | Deferred compensation | Defic accumu during develop sta |
|---|-----------------|--------|----------------------------------|--------------------------|---|
| | ----- | ----- | ----- | ----- | ----- |
| Issuance of common stock for cash - April 2003 @ \$2.00 (unaudited) | 70,000 | 70 | 139,930 | - | |
| Issuance of common stock for cash - May 2003 @ \$2.00 (unaudited) | 30,000 | 30 | 59,970 | | |
| Deferred compensation (unaudited) | | | | 84,000 | |

Edgar Filing: BIOGENTECH CORP - Form 10QSB

| | | | | | |
|---|---------------|-----------|--------------|--------------|-------|
| Acquisition of Biogentech Corp. of ("Togs for Tykes") | 1,032,000 | 1032 | (101,032) | - | |
| Net loss for the three months ended June 30, 2003 (unaudited) | - | - | - | - | (|
| | ----- | ----- | ----- | ----- | ----- |
| Balance at June 30, 2003 (unaudited) | 20,864,708 \$ | 20,865 \$ | 7,004,913 \$ | (112,000) \$ | (3,9 |
| | ===== | ===== | ===== | ===== | ===== |

The accompanying notes are an integral part of the consolidated financial statements

7

BIOGENTECH CORP. AND SUBIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(a Development Stage Company)

| | Three months ended June 30, | |
|---|-----------------------------|--------------|
| | 2003 | 2002 |
| | ---- | ---- |
| CASH FLOWS FROM OPERATING ACTIVITIES: | | |
| NET LOSS | \$ (653,126) | \$ (784,644) |
| ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES: | | |
| Depreciation and amortization | 5,249 | 5,117 |
| Common stock issued for services | - | 6,000 |
| Exercise of stock options for services | - | - |
| Issuance of stock options for services | - | 350,000 |
| Capital contribution - bonus (related party) | - | 50,000 |
| Amortization of prepaid advertising | - | 3,900 |
| Deferred compensation | 84,000 | 31,250 |
| Beneficial conversion feature expense | - | - |
| Amortization of discount | - | 31,030 |
| Impairment expense | - | - |
| CHANGES IN ASSETS AND LIABILITIES: | | |
| (Increase) in other assets | 2,941 | 10,519 |
| Increase in accounts payable and accrued expenses | 95,320 | 15,103 |
| (Increase) decrease in inventory | 97 | - |
| Increase in due to related parties | 100,471 | 172,500 |
| | ----- | ----- |
| NET CASH FLOWS USED IN OPERATING ACTIVITIES: | (365,048) | (109,225) |
| | ----- | ----- |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | |
| Purchase of property and equipment | (24,884) | (3,489) |
| Increase in patent costs | - | - |
| Merger fees and costs | - | - |
| Increase in deposits | - | - |

Edgar Filing: BIOGENTECH CORP - Form 10QSB

| | | |
|---|----------|---------|
| Increase in website development costs | - | - |
| | - | - |
| NET CASH FLOWS USED IN INVESTING ACTIVITY | (24,884) | (3,489) |
| | ----- | ----- |

The accompanying notes are an integral part of the consolidated financial statements

8

BIOGENTECH CORP. AND SUBIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (CONTINUED)
(a Development Stage Company)

| | Three months ended June 30, | |
|--|-----------------------------|----------|
| | 2003 | 2002 |
| | ---- | ---- |
| CASH FLOWS PROVIDED BY FINANCING ACTIVITIES: | | |
| Payment on contract | - | - |
| Sale of common stock | 200,000 | 102,000 |
| Proceeds from related party advances | 208,500 | 6,000 |
| Payments on related party advances | (10,000) | - |
| Contributed capital | - | - |
| NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES | ----- | ----- |
| | 398,500 | 108,000 |
| | ----- | ----- |
| NET INCREASE IN CASH | 8,568 | (4,714) |
| CASH, BEGINNING OF PERIOD | 2,290 | 7,097 |
| | ----- | ----- |
| CASH, END OF PERIOD | \$ 10,858 | \$ 2,383 |
| | ===== | ===== |
| CASH PAID DURING THE PERIOD FOR INTEREST EXPENSE | \$ - | \$ - |
| | ===== | ===== |
| INCOME TAXES | \$ - | \$ - |
| | ===== | ===== |

NON CASH INVESTING AND FINANCING ACTIVITIES:

For the three months ended June 30, 2002

Edgar Filing: BIOGENTECH CORP - Form 10QSB

During the three months ended June 30, 2002, the Company amortized \$31,250 of deferred compensation relating to the issuance of common shares for future consulting services during the year ended March 31, 2002.

During the three months ended June 30, 2002, the Company issued 6,000 shares of its common stock valued at \$6,000 for consulting services provided, which represented the fair market value on the date of issuance.

On May 5, 2002, a related party transferred 25,000 shares of the Company's common stock valued at \$50,000 to an employee of the Company as a bonus. The fair market value on the date of issuance was \$2.00 per share. The Company has recorded this transaction as a contribution to capital and salary expense for the three months ended June 30, 2002.

The accompanying notes are an integral part of the consolidated financial statements

9

BIOGENTECH CORP. AND SUBIDIARY CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (CONTINUED) (a Development Stage Company)

For the three months ended June 30, 2002 (Continued)

During May 2002, the Company granted stock options to three consultants to purchase a total of 300,000 shares at an exercise price of \$1.00 per share. The options vest immediately on the execution date of the consulting agreement. At the date of the grant, the fair value of the common stock was \$2.00 per share. We have valued these options under the Black-Scholes model with a total valuation of approximately \$350,000, which was included in the statements of operations for the three months ended June 30, 2002.

During the year ended March 31, 2002, the Company issued 15,600 shares of its common stock valued at \$15,600 for prepaid advertising expense. The Company has recognized \$3,900 of advertising expense relating to the issuance during the three months ended June 30, 2002.

During the three months ended June 30, 2002, the Company recorded interest expense totaling \$31,030 relating to the discount on a note payable.

For the three months ended June 30, 2003:

The Company has recognized deferred compensation expense totaling \$84,000 relating to options, issued during the year ended March 31, 2003, during the three months ended June 30, 2003.

10

Edgar Filing: BIOGENTECH CORP - Form 10QSB

BioGentech Corp. and Subsidiary
Notes to Consolidated Financial Statements (Unaudited)
For the Three months Ended June 30, 2003 and 2002

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Basis of presentation

The unaudited financial statements have been prepared by BioGentech Corp. (the "Company"), pursuant to the rules and regulations of the Securities and Exchange Commission. (See Reverse Acquisition section below). The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes for the fiscal years ended March 31, 2003 and 2002 included on Form 8K/A as filed with the Securities and Exchange Commission on July 18, 2003.

The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year.

Reverse acquisition

BioGentec Incorporated ("BG"), a private Nevada corporation, was incorporated on November 21, 2000 according to the laws of Nevada, under the name St Petka, Inc. On May 4, 2001, BG formally changed its name to BioGentec Incorporated. On July 2, 2003, BG was merged into Togs for Tykes Acquisition Corp. ("TTAC"), a wholly-owned subsidiary formed for the purpose of acquiring BG. TTAC is the wholly-owned subsidiary of the registrant, BioGentech Corp. ("BGTH") (formerly Togs for Tykes, Inc.). As allowed under SFAS 141, the Company designated a dated of convenience of the closing for accounting purposes as June 30, 2003. Under the terms of the merger agreement, all of BG's outstanding common stock (19,832,708 shares of \$0.0001 par value stock) will be exchanged for 19,832,708 shares newly issued shares of \$0.001 par value stock of BioGentech Corp. common stock. At the date of the transaction, BGTH had 5,532,000 shares of common stock outstanding of which 4,500,000 will be cancelled as part of the transaction leaving 20,864,708 shares outstanding. As of the date of this filing, BG's shares have not been exchanged for BGTH's common stock and the 4,500,000 shares have not been cancelled. An internal review of BG's shareholder register and related supporting documents was undertaken concurrently with the merger and prior to passing such records to the transfer agent for the issuance of the exchanged shares. The review project is complete and the stock register will be forwarded to the transfer agent for processing.

This transaction was consummated with the filing of the Articles of Merger with the State of Nevada on July 2, 2003. BG shareholders then effectively controlled approximately 95% of the issued and outstanding common stock of BGTH. Since the shareholders of BG obtained control of BGTH, according to FASB Statement No. 141 - "BUSINESS COMBINATIONS," this acquisition has been treated as a recapitalization for accounting purposes, in a manner similar to reverse acquisition accounting. In accounting for this transaction:

- i) BG is deemed to be the purchaser and surviving company for accounting purposes. Accordingly, its net assets are included in the balance sheet at their historical book values and the results of operations of BG have been presented for the comparative prior period; and

Edgar Filing: BIOGENTECH CORP - Form 10QSB

- ii) Control of the net assets and business of BGTH was acquired for accounting purposes effective June 30, 2003. This transaction has been accounted for as a purchase of the assets and liabilities of BGTH by BG during the three months ended June 30 2003. The historical cost of the net assets acquired was \$0 and \$100,000 cash was paid.

11

BioGentech Corp. and Subsidiary
Notes to Consolidated Financial Statements (Unaudited)
For the Three months Ended June 30, 2003 and 2002

Going concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Through June 30, 2003, the Company is still in the development stage and has not been able to generate any sufficient revenue from its operations to cover its costs and operating expenses. Although the Company has been able to issue its common stock through private placements to raise capital in order to fund its operations, it is not known whether the Company will be able to continue this practice, or be able to obtain other types of financing or if its revenue will increase significantly to be able to meet its cash operating expenses. This, in turn, raises substantial doubt about the Company's ability to continue as a going concern. Management anticipates revenue to grow as a result of additional products offered to its customers and through its acquisition of InnoFood, Inc. Management believes that the private equity financing, public equity financing and new product offerings will enable the Company to generate positive operating cash flows and continue its operations. However, no assurances can be given as to the success of these plans. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

During April 2003, a definitive agreement was signed between BioGentec Incorporated and (BGTH) to merge BioGentec into BGTH's wholly-owned subsidiary, Togs for Tykes Acquisition Corp. The merger was consummated with the filing of the merger agreement with the State of Nevada in July 2003. As a result of the merger, the Company intends to gain access to public equity markets and additional financing.

In July 2003, the Company signed a definitive agreement to acquire InnoFood, Inc. As of the date of this filing, the transaction has not closed. (see Subsequent Events and management, discussion and analysis section).

Stock Options

We did not grant any new options and no options were cancelled or exercised during the three months ended June 30, 2003. As of June 30, 2003, 1,150,000 options were outstanding., all of which are fully vested. Accordingly, no additional disclosure is required under SFAS 148.

Edgar Filing: BIOGENTECH CORP - Form 10QSB

Earnings (loss) per share

We have adopted Statement of Financial Accounting Standards No. 128 ("SFAS 128"), "Earnings Per Share." Under SFAS 128, basic earnings per share is computed by dividing income available to common stockholders by the weighted-average number of common shares assumed to be outstanding during the period of computation. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Because we have incurred net losses, basic and diluted loss per share are the same as additional potential common shares would be anti-dilutive. As of June 30, 2003 we have approximately 1,150,000 common stock equivalents.

Recent Accounting Pronouncements:

During April 2003, the FASB issued SFAS 149 - "Amendment of Statement 133 on Derivative Instruments and Hedging Activities", effective for contracts entered into or modified after June 30, 2003, except as stated below and for hedging relationships designated after June 30, 2003. In addition, except as stated below, all provisions of this Statement should be applied prospectively. The provisions of this Statement that relate to Statement 133 Implementation Issues that have been effective for fiscal quarters that began prior to June 15, 2003, should continue to be applied in accordance with their respective effective dates. In addition, paragraphs 7(a) and 23(a), which relate to forward purchases or sales of when-issued securities or other securities that do not yet exist, should be applied to both existing contracts and new contracts entered into after June 30, 2003. The Company does not participate in such transactions, however, is evaluating the effect of this new pronouncement, if any, and will adopt FASB 149 within the prescribed time.

12

BioGentech Corp. and Subsidiary
Notes to Consolidated Financial Statements (Unaudited)
For the Three months Ended June 30, 2003 and 2002

During May 2003, the FASB issued SFAS 150 - "Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity", effective for financial instruments entered into or modified after May 31, 2003, and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003. This Statement establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. It requires that an issuer classify a freestanding financial instrument that is within its scope as a liability (or an asset in some circumstances). Many of those instruments were previously classified as equity. Some of the provisions of this Statement are consistent with the current definition of liabilities in FASB Concepts Statement No. 6, Elements of Financial Statements. The Company is evaluating the effect of this new pronouncement and will adopt FASB 150 within the prescribed time.

2. Related-Party Transactions

- a) BioGentec has a consulting contract with R&R Development, Inc

Edgar Filing: BIOGENTECH CORP - Form 10QSB

("R&R") whereby R&R would provide managerial consulting services to the Company at the rate of \$125,000 per year and the rate shall increase to \$135,000 per year when and if BioGentec completes a merger with a public shell company. R&R is also a shareholder of BioGentec. For the three months ended June 30, 2003, the Company accrued \$31,250 under this contract.

During the period from April 1, 2003 to June 30, 2003, R&R advanced BioGentec cash totaling \$208,500. These transactions have been recorded as a demand note payable. The Company has imputed interest on the note at a rate of 10% per annum. Interest expense totaling \$6,721 was accrued for the period ended June 30, 2003.

- b) The President (previously the Executive Vice President) entered into an employment agreement dated November 22, 2000, amended on December 31, 2001, which pays an annual salary of up to \$125,000 and certain bonuses. For the three months ended June 30, 2003, the Company accrued \$31,250 of salary for the President.
- c) BioGentec has entered into an employment agreement with the Chief Operating Officer ("COO") that pays an annual salary of \$120,000 per year. As of June 30, 2003, the Company owed the COO approximately \$40,000 on the agreement, which is, included in accounts payable and accrued expenses.

3. Sale of Common Stock

During the three months ended June 30, 2003, BioGentec Incorporated sold 100,000 restricted common shares in a private placement at \$2.00 per share, which represented the fair market value of the common stock.

4. Subsequent Events

InnoFood, Inc. Agreement

On July 31, 2003, the Company entered into a definitive agreement to acquire InnoFood, Inc. ("InnoFood"), owner of certain rights to a proprietary food processing technology developed by Modofood S.P.A. of Brescia, Italy. The agreement provides BioGentech exclusive manufacturing and distribution rights of Modofood's proprietary food sterilization and preservation technology for North America, Central America, South America and Japan, as well as the exclusive rights to negotiate on behalf of Modofood for Southeast Asia, including Taiwan, China and Indonesia.

Under terms of the agreement, InnoFood shareholders will receive one BioGentech common share and one BioGentech warrant share for every twelve shares of InnoFood common stock. InnoFood shareholders will also receive one InnoFood preferred share for every 1,200 InnoFood common shares. The agreement calls for BioGentech to infuse \$5 million of working capital prior to December 31, 2003. As of August 20, 2003, the transaction has not closed, but the Company has issued 3.5 million common shares of stock which are being held in escrow relating to this agreement.

Edgar Filing: BIOGENTECH CORP - Form 10QSB

ITEM 2. PLAN OF OPERATION

THIS FOLLOWING INFORMATION SPECIFIES CERTAIN FORWARD-LOOKING STATEMENTS OF MANAGEMENT OF THE COMPANY. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT ESTIMATE THE HAPPENING OF FUTURE EVENTS AND ARE NOT BASED ON HISTORICAL FACT. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, SUCH AS "MAY", "SHALL", "COULD", "EXPECT", "ESTIMATE", "ANTICIPATE", "PREDICT", "PROBABLE", "POSSIBLE", "SHOULD", "CONTINUE", OR SIMILAR TERMS, VARIATIONS OF THOSE TERMS OR THE NEGATIVE OF THOSE TERMS. THE FORWARD-LOOKING STATEMENTS SPECIFIED IN THE FOLLOWING INFORMATION HAVE BEEN COMPILED BY OUR MANAGEMENT ON THE BASIS OF ASSUMPTIONS MADE BY MANAGEMENT AND CONSIDERED BY MANAGEMENT TO BE REASONABLE. OUR FUTURE OPERATING RESULTS, HOWEVER, ARE IMPOSSIBLE TO PREDICT AND NO REPRESENTATION, GUARANTY, OR WARRANTY IS TO BE INFERRED FROM THOSE FORWARD-LOOKING STATEMENTS.

THE ASSUMPTIONS USED FOR PURPOSES OF THE FORWARD-LOOKING STATEMENTS SPECIFIED IN THE FOLLOWING INFORMATION REPRESENT ESTIMATES OF FUTURE EVENTS AND ARE SUBJECT TO UNCERTAINTY AS TO POSSIBLE CHANGES IN ECONOMIC, LEGISLATIVE, INDUSTRY, AND OTHER CIRCUMSTANCES. AS A RESULT, THE IDENTIFICATION AND INTERPRETATION OF DATA AND OTHER INFORMATION AND THEIR USE IN DEVELOPING AND SELECTING ASSUMPTIONS FROM AND AMONG REASONABLE ALTERNATIVES REQUIRE THE EXERCISE OF JUDGMENT. TO THE EXTENT THAT THE ASSUMED EVENTS DO NOT OCCUR, THE OUTCOME MAY VARY SUBSTANTIALLY FROM ANTICIPATED OR PROJECTED RESULTS, AND, ACCORDINGLY, NO OPINION IS EXPRESSED ON THE ACHIEVABILITY OF THOSE FORWARD-LOOKING STATEMENTS. WE CANNOT GUARANTY THAT ANY OF THE ASSUMPTIONS RELATING TO THE FORWARD-LOOKING STATEMENTS SPECIFIED IN THE FOLLOWING INFORMATION ARE ACCURATE, AND WE ASSUME NO OBLIGATION TO UPDATE ANY SUCH FORWARD-LOOKING STATEMENTS.

CRITICAL ACCOUNTING POLICY AND ESTIMATES. Our Management's Discussion and Analysis of Financial Condition and Results of Operations section discusses our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources, including patents. These accounting policies are described at relevant sections in this discussion and analysis and in the notes to the financial statements included in our Quarterly Report on Form 10-QSB for the period ended June 30, 2003.

OUR BACKGROUND. We were incorporated in Nevada on September 26, 1997, as Aztec Ventures, Inc. Our original business was the sale of pay phone services. In June 2001, our management and business changed. On September 5, 2001, we amended our Articles of Incorporation to change our name to Togs for Tykes, Inc. due to the shift of our business to designing and marketing children's apparel. Since we were not successful in implementing that business plan due to lack of funds, in March 2003, we entered into negotiations regarding an acquisition of BioGentec

Edgar Filing: BIOGENTECH CORP - Form 10QSB

Incorporated, a Nevada corporation ("BG"), in order to merge it with and into our wholly-owned subsidiary, Togs for Tykes Acquisition Corporation, a Nevada corporation. By means of a shareholder vote in March 2003, we changed our name to Biogentech Corp.

We entered into an Agreement and Plan of Merger with BG which provided that BG would become our subsidiary by merging with our acquisition subsidiary. That agreement is attached as an exhibit to our report on Form 8-K filed on July 3, 2003. On July 2, 2003, our subsidiary filed Articles of Merger with the Secretary of State of Nevada to complete that acquisition for accounting purposes, the company has deemed the transaction closed as of June 30, 2003. We anticipate that the acquisition will increase the total value of the corporation to our investors. Also in July 2003, we changed our fiscal year end from December 31 to March 31.

BIOGENTEC INCORPORATED. BioGentec Incorporated ("BG") was incorporated in Nevada on November 21, 2000. BG is dedicated to the development and commercialization of consumer medical products and life style - health improvement products. BG's first product focus is in the fields of immunomodulation, menopause, pinpoint detoxification and cholesterol reduction. BG anticipates that its initial patented product, Prehistin, (formerly Allertin, will create a unique niche within the allergy relief category. In November 2000, BG acquired Allergy Limited, LLC ("Allergy Limited"). Allergy Limited sponsored the clinical research for Prehistin's formula from 1989 through 2000 and secured the first patent, in 1992 and BG secured the second in 2001. Please refer to our Form 8-K filed on July 16, 2003 and the first amendment filed on July 18, 2003, for a more detailed discussion on the Biogentec Incorporated's business and management.

14

For the three month period ended June 30, 2003.

LIQUIDITY AND CAPITAL RESOURCES. We had cash of \$10,858 at June 30, 2003. We also had \$545 in other assets and \$5,903 in inventory, making our total current assets as at June 30, 2003 equal to \$17,306. We also had the following fixed assets: \$79,382 in net fixed assets, \$12,650 represented by our website, \$40,000 in deposits and \$3,850,000 represented by net value of our patents. Therefore, our total assets as of June 30, 2003 totaled \$3,999,338. Our total current liabilities were \$1,049,599 at June 30, 2003, which was represented by accounts payable and accrued expenses of \$452,446 and \$597,133 due to related parties or shareholders.

We have financed our operations primarily through cash generated from related party debt financing and from the private placement sale of equity securities. During the three month ended June 30, 2003, BG sold 100,000 common shares of its common stock for \$2.00 per share and received \$200,000. Additionally related parties loaned \$208,500 to BG. In the three month period ended June 30, 2002, BG sold \$102,000 in common stock and received \$6000 in related party loans.

As of June 30, 2003, we had negative working capital of \$1,032,293 an increase of \$488,833 (76%) as compared to June 30, 2002, due primarily to an increase in related party obligations and compensation.

Our net cash used by operating activities was \$365,048 for the three months ended June 30, 2003 as compared to net cash used of \$109,225 for the three

Edgar Filing: BIOGENTECH CORP - Form 10QSB

months ended June 30, 2002, an increase of \$225,833 or 207%, primarily due to a reduction of non-cash equity and expense transactions.

Our cash used in investing activities was \$24,884 for the three month period ended June 30, 2003, an increase of \$21,395 or 613%, due to the purchase of computer equipment.

Our net cash provided by financing activities was \$398,500 for the three months ended June 30, 2003 compared to \$108,000 for the same period a year earlier, an increase of 269%. The increase is primarily due to increases in the sale of common stock and loan proceeds from related parties.

See Subsequent Events section for a discussion of capital requirements related to acquisition of InnoFood and financing obtained subsequent to June 30, 2003.

RESULTS OF OPERATIONS.

Revenues and Cost of Sales: Revenues for the quarters ended June 30, 2003 and 2002 are insignificant as we are undertaking a Phase III clinical trial in order to obtain FDA approval as an over the counter drug.

Operating Expenses: Operating expenses for the quarter ended June 30, 2003 were \$647,425 as compared to \$747,284 for the quarter ended June 30, 2002. For both periods expenses incurred were for two major purposes: ongoing development of our Prehistin product and related product management and ii) general management and fund raising efforts. Expenses decreased \$99,859 due primarily to reduced compensation and consulting expenses.

15

Our net loss for three months ended June 30, 2003, was \$653,126 (\$0.03 per share loss) compared to a net loss of \$784,644 (\$0.05 per share loss) for the corresponding period in 2002. Our net loss for the period from our inception to June 30, 2003, was \$3,964,039 (a loss of \$0.23 per share).

Our Plan of Operation for the Next Twelve Months. Over the next 12 months, we plan on pursuing the product development begun by Biogentec Incorporated. Specifically, we plan on moving forward with the development, marketing and sale of our Prehistin product and related products. We also hope that the transaction with InnoFood will close. Should it close, we will pursue the manufacturing and distribution of Modofood's proprietary food sterilization and preservation technology in North America, Central America, South America and Japan, as well as the exclusive rights to negotiate on behalf of Modofood for Southeast Asia, including Taiwan, China and Indonesia.

At June 30, 2003, we had cash of \$10,858. Subsequent to June 30, 2003, we expect to receive a loan in the amount of \$2,088,000 from International Business Consultants, GmbH. The total amount of the loan is \$2.4 Million and is collateralized with 3.5 million in our common stock with a loan to value of our common stock of twenty-five (25) percent. The loan has a two year term at 6% interest, paid quarterly. We will be required to raise additional funds in order to pursue the further development and marketing of the Prehistin product. We will also be required to raise additional funds to manufacture and market Modofood's product. In that regard, we plan on raising additional financing through private placements or other offerings of our stock. We may attempt to secure other loans from lending institutions or otherwise. There is no guarantee that we will be able to raise additional funds through offerings or otherwise.

Edgar Filing: BIOGENTECH CORP - Form 10QSB

If we are unable to raise funds, our ability to continue with product development and to complete the final closing with InnoFood will be hindered.

During the next twelve months, we plan on moving forward with the FDA approval process related to our Prehistin product. We are also in the process of developing additional related products. Such development is in its infancy. Other than the research and development related to our Prehistin product, we do not plan to engage in any other research and development unless we are able to raise additional funds.

We do anticipate the purchase of significant equipment within the next 12 months for InnoFood.

We do not anticipate any significant hiring up to fifty (50) people over the next 12 months for InnoFood and other product lines, assuming we are able to close the InnoFood transaction described above.

ITEM 3. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures. We maintain controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. Based upon their evaluation of those controls and procedures performed as of June 30, 2003, our chief executive officer and the principal financial officer concluded that our disclosure controls and procedures were adequate.

(b) Changes in internal controls. There were no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to the date of the evaluation of those controls by the chief executive officer and principal financial officer.

PART II -- OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

As of March 31, 2003, BioGentec Incorporated, which is as of the date of this report our wholly owned subsidiary, vacated previously occupied office space and is in a dispute with the prior landlord. The landlord has filed suit against us in the County of Orange, Superior Court of California, Case #03CC02904. We believe that the landlord breached the agreement and that we will successfully defend ourselves.

ITEM 2. CHANGES IN SECURITIES.

On June 19, 2003, we filed a certificate of amendment to our Articles of Incorporation to effect an increase in our authorized common stock from 20,000,000 to 50,000,000 shares.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Edgar Filing: BIOGENTECH CORP - Form 10QSB

None.

ITEM 4. SUBMISSION OF MATTERS TO VOTE OF SECURITY HOLDERS

On March 24, 2003 shareholders representing a majority of our issued and outstanding common stock voted to increase our authorized shares of common stock from 20,000,000 to 50,000,000, and to change our name to Biogentech Corp. Both of these actions were effected by filing a certificate of amendment to our Articles of Incorporation on with the State of Nevada on June 19, 2003.

ITEM 5. OTHER INFORMATION

None during the reporting period. However, subsequent to the reporting period, on July 15, 2003, the Registrant's Board of Directors approved a change in the Registrant's fiscal year end from December 31st to March 31st. The Registrant's next fiscal year will begin on April 1st and end on March 31st of each year, effective with the year beginning April 1, 2004.

Reference is also made to the audited financial reports for the years ending March 31, 2003 and March 31, 2002 for BioGentec Incorporated which were filed with our report on Form 8-K on July 3, 2003 as amended, regarding our subsidiary's acquisition of BioGentec Incorporated and other events. We expect to file subsequent Quarterly Reports on Form 10-QSB on or before the due dates of November 15, 2003 and February 14, 2004, and to file our next Annual Report on Form 10-KSB on or before June 30, 2004.

On July 31, 2003 we entered into a definitive agreement to acquire InnoFood, Inc. ("InnoFood"), owner of certain rights to a proprietary food processing technology developed by Modofood S.P.A. of Brescia, Italy. The agreement provides exclusive manufacturing and distribution rights of Modofood's proprietary food sterilization and preservation technology for North America, Central America, South America and Japan, as well as the exclusive rights to negotiate on behalf of Modofood for Southeast Asia, including Taiwan, China and Indonesia.

Under terms of the agreement, InnoFood shareholders will receive one share of our common stock and a warrant to purchase one share of our common stock for every twelve shares of InnoFood common stock. InnoFood shareholders will also receive one share of our preferred stock for every 1,200 InnoFood common shares. The agreement calls for us to infuse \$5 million of working capital prior to December 31, 2003. As of August 20, 2003, this transaction has not closed.

See Subsequent Events in the notes to our finance statements for a discussion of capital requirements related to the acquisition of InnoFood and financing obtained subsequent to June 30, 2003.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

On June 25, 2003, we filed a report on Form 8-K to disclose the filing of the certificate of amendment to our Articles of Incorporation on with the State of Nevada on June 19, 2003, effecting the increase in our authorized shares of common stock from 20,000,000 to 50,000,000, and our name change to Biogentech Corp. Both of these actions were approved in March 2003 by vote of shareholders holding a majority of our issued and outstanding common stock.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Biogenetech Corp.,
a Nevada corporation

August 27, 2003

By: /s/ Chaslav Radovich

Chaslav Radovich

Its: Chief Executive Officer, President,
Director

CERTIFICATIONS

I, Chaslav Radovich, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Biogenetech Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Edgar Filing: BIOGENTECH CORP - Form 10QSB

- (b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation and
 - (c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting , to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant`s internal control over financial reporting.

Date: August 27, 2003

/s/ Chaslav Radovich

Chaslav Radovich
Chief Executive Officer and Chief Financial Officer